Meningococcal disease is a severe, fast-progressing infection; vaccination is key for high-risk groups, preventing ...

Infants randomized to the 9-month age group were then further randomized in a 2:1 ratio to receive a single dose of the investigational meningococcal vaccine Men5CV (brand name MenFive ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

The vaccine was approved by the Food and Drug Administration last week for ages 10 through 25. However, the CDC's advisory panel voted to add the new vaccine option for people 16 through 23 ...

Back-to-school season is around the corner, are your children prepared? Back to school means new clothes, new school supplies ...

Pfizer’s new meningococcal vaccine, Penbraya, protects against five kinds of bacteria and could soon be an option that offers people broad protection from meningococcal disease with fewer shots.

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Penbraya, the meningococcal vaccine approved by the FDA on Friday, combines Nimenrix and Trumenba in a single shot. The regulatory decision covers use of this new vaccine in those ages 10 through 25.

Both the CDC and VDH are encouraging parents to make sure children receive the meningococcal conjugate vaccine (MenACWY) at age 11 or 12 and a follow-up booster at age 15 or 16.

Many pediatricians and family physicians don’t discuss the meningococcal B vaccine with teens even though these conversations are recommended to determine whether adolescents should get shots to ...

The Bottom Line "Identifying contributing factors to low vaccine uptake, such as the association between local deprivation and uptake of meningococcal vaccines, should be of public health ...